TICKERNERD
Menu
LBRXLBRXHealthcare · Biotechnology

LBRX Stock Forecast: LB Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$42
+0.78% on the day

The 8 Wall Street analysts covering LB Pharmaceuticals, Inc. hold a median 12-month price target of $54 — +26.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 6 of 100 as at 19 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.4B
Ticker Nerd rank
6 / 100
Median analyst target
$54
Analysts covering
8
Revenue$0.0
Operating income−$53.9M
Net income−$51.6M
Free cash flow−$38.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.8%
1M
−12.9%
YTD
+90.8%
1Y
+165.1%
From 52W high
−14.2%
From 52W low
+190.7%
$15
$49
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LBRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores LB Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
6 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
59
Size
40
Quality
32
Revisions
27
Volatility
23
Momentum
21
Issuance
17
Accruals
17
Growth
10

Value (59): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Growth (10): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LBRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LBRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80Oct 25Jan 26Apr 26Jul 26LBRXHigh $78Median $54Low $37

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
8 Buy0 Hold0 Sell
Low $37Median $54High $78

The green dot is the last close — the median target sits +26.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
24 Aug 2026HC Wainwright & Co.MaintainsBuy$45 → $60
12 Aug 2026BMO CapitalMaintainsOutperform—
12 Aug 2026BMO CapitalMaintainsOutperform$46 → $54
3 Aug 2026HC Wainwright & Co.ReiteratesBuy—
3 Aug 2026HC Wainwright & Co.ReiteratesBuy$45
21 July 2026BMO CapitalInitiatesOutperform$46
21 July 2026BMO CapitalInitiatesOutperform—
7 July 2026Wolfe ResearchInitiatesOutperform—
7 July 2026Wolfe ResearchInitiatesOutperform$45
27 Apr 2026HC Wainwright & Co.InitiatesBuy—
10 Apr 2026Craig-HallumInitiatesBuy—
27 Mar 2026StifelMaintainsBuy—
11 Dec 2025StifelMaintainsBuy—
6 Oct 2025Leerink PartnersInitiatesOutperform—
6 Oct 2025Piper SandlerInitiatesOverweight—
6 Oct 2025StifelInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LBRX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

LBRX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, LB Pharmaceuticals, Inc. returned +165.1% against +16.3% for the S&P 500, dividends included.

LBRX vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Oct 25Jan 26Apr 26Jul 26LBRXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LBRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
6
Fundamentals

LB Pharmaceuticals, Inc. (LBRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−13.3×

Cheaper than 94% of US stocks

Price / sales
—
Price / book
3.6×

Cheaper than 28% of US stocks

EV / EBITDA
−11.4×

Cheaper than 85% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−50.0%

Higher than 21% of US stocks

Return on assets
−30.0%

Higher than 14% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

LB Pharmaceuticals, Inc. (LBRX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • LB Pharmaceuticals, Inc. has a market value of $1.4B and an enterprise value of $1.0B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$85.7M.

  • Diluted earnings per share, trailing twelve months: $−3.44.

  • Free cash flow in the twelve months to 30 June 2026: −$82.8M.

  • Shares outstanding: 28.7M.

  • Trailing P/E: −13.3×; forward P/E: −8.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • LB Pharmaceuticals, Inc. employs 49 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Sept 2026

Data provided by Twelve Data

Peers

LBRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
LBRXLB Pharmaceuticals, Inc.$1.4B
6
DMRADamora Therapeutics, Inc.$1.4B
42
AVLNAvalyn Pharma, Inc.$1.4B
1
TRAXFirst Tracks Biotherapeutics, Inc.$1.3B
1
DRTSAlpha Tau Medical Ltd.$1.4B
16
ORICOric Pharmaceuticals, Inc.$1.3B
50
AVBPArrivent BioPharma, Inc.$1.4B
37

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own LB Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LBRX news & analysis

LB Pharmaceuticals: One Methyl Group, Two Enantiomers, And A Bullish $5 Billion Opportunity

Seeking Alpha · 18 Sept 2026positive

Seeking Alpha assigns LB Pharmaceuticals a buy rating with a base-case valuation of $85 per share and potential upside to $150 if Phase 3 trials and clinical differentiation succeed. The article highlights LB-102's N-methyl modification, which enables brain receptor occupancy at lower doses than amisulpride, though the clinical benefit of the R-enantiomer's 5-HT7 activity remains unproven.

Why it matters — LBRX watchers would care because the piece outlines LB-102's differentiation potential and its Phase 3 and clinical-outcome milestones as key factors in the drug's valuation.

LB Pharmaceuticals Appoints Susan G. Kozauer, M.D.

GlobeNewsWire · 15 Sept 2026neutral

LB Pharmaceuticals, Inc. announced the appointment of Susan G. Kozauer, M.D. to the company, as disclosed in a Sept. 15, 2026 GlobeNewsWire release. The announcement focuses on the new appointment of the neuromedicines company.

Why it matters — A LBRX watcher would care because management appointments can signal strategic direction and strengthen the leadership of the company developing treatments for underserved brain disorders.

IPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target?

Investors Business Daily · 9 Sept 2026positive

LB Pharmaceuticals, an IPO stock, has more than tripled in value in under a year as investors follow its work in neuropsychiatric disorders. The article questions whether the company could become a takeover target.

Why it matters — LBRX watchers would care because the stock's rapid rise and its progress in neuropsychiatric disorders could draw acquisition interest.

LB Pharmaceuticals to Participate in Upcoming September Investor Events

GlobeNewsWire · 3 Sept 2026neutral

LB Pharmaceuticals announced that members of its executive team will present and participate in several upcoming investor conferences in September. The company made the announcement on September 3, 2026, via GlobeNewsWire.

Why it matters — LBRX watchers may be interested as the presentations could raise the company's visibility among investors ahead of these scheduled events.

LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer

GlobeNewsWire · 3 Sept 2026neutral

LB Pharmaceuticals announced the appointment of Joseph Miller as Chief Financial Officer. The company, which develops therapies for underserved brain disorders, made the announcement on September 3, 2026.

Why it matters — A new CFO appointment signals a change in LB Pharmaceuticals' executive leadership, which LBRX watchers would track for its potential impact on the company's financial management and strategy.

FAQ

Frequently asked questions about LBRX stock

What is the LBRX stock price forecast for 2026-2027?

The 8 Wall Street analysts covering LB Pharmaceuticals, Inc. have a median 12-month price target of $54, with estimates ranging from $37 to $78. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LBRX stock a buy right now?

Of the 8 analysts covering LB Pharmaceuticals, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks LB Pharmaceuticals, Inc. 6 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LBRX?

As at 19 Sept 2026, LB Pharmaceuticals, Inc. ranks 6 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (59 of 100).

Will LBRX stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +26.0% from the last close, and Ticker Nerd's factor model ranks LB Pharmaceuticals, Inc. 6 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LBRX stock forecast for 2030?

No analyst covering LB Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LBRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $37 to $78 over the next 12 months.

How has LBRX stock performed over the past year?

LB Pharmaceuticals, Inc. returned +165.1% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does LB Pharmaceuticals, Inc. do?

LB Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases.

What is the latest news on LBRX?

The most recent item we track (Seeking Alpha, 18 Sept 2026): "LB Pharmaceuticals: One Methyl Group, Two Enantiomers, And A Bullish $5 Billion Opportunity". Seeking Alpha assigns LB Pharmaceuticals a buy rating with a base-case valuation of $85 per share and potential upside to $150 if Phase 3 trials and clinical differentiation succeed. The article highlights LB-102's N-methyl modification, which enables brain receptor occupancy at lower doses than amisulpride, though the clinical benefit of the R-enantiomer's 5-HT7 activity remains unproven.

Company

About LB Pharmaceuticals, Inc.

LB Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead program, LB-102, is an oral small-molecule candidate being advanced for acute schizophrenia and studied across additional psychiatric indications, including bipolar I depression and major depressive disorder. The company’s work centers on central nervous system medicines designed to address unmet needs in severe mental health disorders, with an emphasis on improving treatment options through differentiated pharmacology. LB Pharmaceuticals Inc. operates as a specialized drug developer within the healthcare sector and focuses on moving its pipeline through clinical development toward potential commercialization.

CEO Ms. Heather D. Turner Esq., J.D. · 49 employees · United States · https://lbpharma.us